礼来与诺和诺德报告：GLP-1类药物减缓生物衰老生物标志物。
在衰老研究与药物发现大会上，制药制造商诺和诺德和礼来展示了数据，显示其GLP-1药物可降低生物衰老的分子标志物。
Eli Lilly and Novo Nordisk Report GLP-1 Drugs Slow Biological Aging Biomarkers At the Aging Research & Drug Discovery conference, pharmaceutical manufacturers Novo Nordisk and Eli Lilly presented data showing their GLP-1 medications reduce molecular markers of biological aging.
诺和诺德利用蛋白质组学时钟分析了10,052名临床试验参与者的血液样本，发现司美格鲁肽使各组织的生物年龄减少了两到三年，心脏蛋白甚至减少了四年，相比安慰剂组。
Novo Nordisk analyzed blood samples from 10,052 clinical trial participants using proteomic clocks, finding semaglutide reduced biological age by two to three years across tissues, and up to four years for heart proteins compared to a placebo.
礼来在一项评估替尔泊肽的表观遗传时钟研究中观察到分子衰老减缓的类似现象。
Eli Lilly observed similar slowing of molecular aging in an epigenetic clock study evaluating tirzepatide.
研究人员指出，这些效果已在超重和糖尿病人群中得到确认，但在健康人群中的疗效和安全性仍未经验证。
Researchers noted the effects are confirmed in overweight and diabetic cohorts, though efficacy and safety in healthy populations remain unverified.
肌肉流失等担忧依然存在，而由ARPA-H资助的3800万美元研究正在继续评估司美格鲁肽在老年人中的抗衰老效果。
Concerns such as muscle loss persist, while a $38 million study funded by ARPA-H continues to evaluate semaglutide's anti-aging effects in older adults.